Journal of Literature Pharmacy Sciences

Aşı Kararsızlığı ve COVID-19'un Etkileri
Vaccine Hesitancy and Effects of COVID-19
Pınar ERKEKOĞLUa,b, Selinay Başak ERDEMLİ KÖSEa,c, Aylin BALCIa, Anıl YİRÜNa,d
aHacettepe Üniversitesi Eczacılık Fakültesi, Farmasötik Toksikoloji ABD, Ankara, Ankara TÜRKİYE
bHacettepe Üniversitesi Aşı Enstitüsü, Aşı Teknolojisi ABD, Ankara, TÜRKİYE
cBurdur Mehmet Akif Ersoy Üniversitesi Fen-Edebiyat Fakültesi, Biyokimya ABD, Burdur, TÜRKİYE
dÇukurova Üniversitesi Eczacılık Fakültesi, Farmasötik Toksikoloji ABD, Adana, TÜRKİYE
J Lit Pharm Sci. 2020;9(2):208-20
doi: 10.5336/pharmsci.2020-76102
Article Language: TR
Full Text
ÖZET
 Dünya Sağlık Örgütü, aşıları; 'immün sistemimizin, virüs ve bakteri gibi patojenleri tanıyıp onlarla savaşmasını sağlayan ve bunların oluşturduğu hastalıklara karşı vücudumuzu koruyan farmasötik ürünler' olarak tanımlamıştır. Aşılar her yıl milyonlarca çocuğun hayatını kurtarmakta, hastalıkların ve sakatlıkların önlenmesini sağlamaktadır. Buna rağmen 'aşı kararsızlığı', aşılamadaki gecikmelere/redde ve aşıyla önlenebilir hastalık salgınlarına yol açma potansiyeli nedeni ile endişe vericidir. Aşı tereddüdünün nedenleri, söz konusu aşıya/aşılara isteksizliği ifade eden bireylere/gruplara göre değişebilir. Bu nedenlerin dikkatle değerlendirilmesi ve bunlara yönelik çözümler aranması gerekmektedir. Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)], SARS-CoV-2 virüsünün neden olduğu 'şiddetli akut solunum sendromu'dur. İlk olarak Çin'in Hubei bölgesinin Wuhan şehrinde görüldüğü düşünülen bu hastalık, hızla tüm dünyaya yayılmıştır. Hastalığın seyrinde yaş, cinsiyet, daha önceden var olan hastalık durumu gibi faktörlerin etkili olduğu bilinmektedir. Dünya genelinde çok ciddi halk sağlığı sorunlarına ve ekonomik krizlere neden olan bu hastalığı kesin olarak tedavi ettiği bilinen bir ilaç veya aşı henüz bulunamamıştır. Geçmişte aşı karşıtlığı fikirlerini dile getiren birçok kişinin, COVID-19 aşısının bulunması konusunda bugün beklenti içinde olduğu bir gerçektir. Aşılama, enfeksiyon hastalıklarından korunmanın yanı sıra, enfeksiyon hastalıkları nedeni ile oluşan ciddi sakatlıkların veya ölümlerin azaltılmasında da en etkin yöntemdir. Bu nedenle aşı kararsızlığını önlemek için gereksinim duyulan stratejilerin, ülkeler temelinde geliştirilmesi ve takiben küresel bir stratejik yaklaşımın benimsenmesi gereklidir. Bu derleme kapsamında aşı kararsızlığı, nedenleri, sonuçları ve COVID-19'dan sonra aşılamaya toplumun genel bakış açısındaki değişiklikler tartışılacaktır.

Anahtar Kelimeler: Aşı; aşı karşıtlığı; aşı tereddüdü; COVID-19
ABSTRACT
 World Health Organization defined vaccines as 'pharmaceutical products that helps body's immune system to recognize and fight pathogens like viruses or bacteria, which then keeps us safe from diseases they cause'. Vaccines save lives of millions of children, prevent diseases and disabilities every year. Nevertheless, 'vaccine hesitancy' is alarming due to its potential to cause delays/rejections in vaccination and vaccine-preventable disease outbreaks. Reasons of vaccination hesitancy may vary according to individuals/groups expressing reluctance to certain type of vaccine/s. These reasons should be carefully evaluated and solutions should be sought. Coronavirus disease-2019 (COVID-19) is 'severe acute respiratory syndrome' caused by SARS-CoV-2 virus. The disease was thought to be first observed in Wuhan city of Hubei region of China and it spread rapidly all over the world. Several factors like age, gender, and coexisting diseases are known to be effective in course of the disease. There is still no drug or vaccine, known to cure this disease, which causes serious public health problems and economic crises worldwide. It is a fact that many people expressing their antivaccination ideas in the past are in expectation of a COVID-19 vaccine today. Along with protection from infectious diseases, vaccination is the most effective way to reduce serious morbidities or mortalities caused by infectious diseases. Therefore, strategies for preventing vaccine hesitancy must be developed on country basis and later a global strategic approach should be considered. In this review vaccine hesitancy, causes, consequences and changes in general view of society on vaccination after COVID-19 will be discussed.

Keywords: Vaccine; anti-vaccination; vaccine hesitancy; COVID-19
REFERENCES:
  1. World Health Organization. Health Topics. Vaccines and Immunization. (Erişim tarihi: 20.4.2020) https://www.who.int/topics/vaccines/en/
  2. World Health Organization. Health Topics. Immunization. (Erişim tarihi: 20.4.2020) https://www.who.int/topics/immunization/en/
  3. Schuchat A. Human vaccines and their importance to public health. Procedia in Vaccinology. 2011;5:120-6. [Crossref] 
  4. Barras V, Greub G. History of biological warfare and bioterrorism. Clin Microbiol Infect. 2014;20(6):497-502. [Crossref]  [PubMed] 
  5. Slifka MK, Hanifin JM. Smallpox: the basics. Dermatol Clin. 2004;22(3):263-74,vi. [Crossref]  [PubMed] 
  6. Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc B Biol Sci. 2014;369(1645):20130433. [Crossref]  [PubMed]  [PMC] 
  7. Bloom DE, Canning D, Seiguer E. The effect of vaccination on children's physical and cognitive development in the Philippines. Program on the Global Demography of Aging Working Paper Series, 2010. (Erişim tarihi: 02.01.2020) https://core.ac.uk/download/pdf/6494802.pdf
  8. World Health Organization. Macroeconomics and health: investing in health for economic development. Commission on Macroeconom­ics and Health. Geneva: World Health Organ­ization; 2001. (Erişim Tarihi: 20.04.2020) https://apps.who.int/iris/bitstream/handle/10665/42435/924154550X.pdf
  9. World Health Organization. Immunization, Vaccines and Biologicals. Global Vaccine Action Plan 2011-2020. https://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/
  10. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305-6. [Crossref]  [PubMed] 
  11. Peeples L. News feature: avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci U S A. 2020;117(15):8218-21. [Crossref]  [PubMed]  [PMC] 
  12. Dubé E, Vivion M, MacDonald NE. Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: influence, impact and implications. Expert Rev Vaccines. 2015;14(1):99-117. [Crossref]  [PubMed] 
  13. Facciolà A, Visalli G, Orlando A, Bertuccio MP, Spataro P, Squeri R, et al. Vaccine hesitancy: an overview on parents' opinions about vaccination and possible reasons of vaccine refusal. J Public Health Res. 2019;8(1):1436. [Crossref]  [PubMed]  [PMC] 
  14. Shen SC, Dubey V. Addressing vaccine hesitancy: clinical guidance for primary care physicians working with parents. Can Fam Physician. 2019;65(3):175-81. [PubMed] 
  15. SAGE. Report of the SAGE Working Group on Vaccine Hesitancy. 2014. (Erişim tarihi:20.04.2020) https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf
  16. Larson HJ, Jarrett C, Schulz WS, Chaudhuri M, Zhou Y, Dube E, et al; SAGE Working Group on Vaccine Hesitancy. Measuring vaccine hesitancy: the development of a survey tool. Vaccine. 2015;33(34):4165-75. [Crossref]  [PubMed] 
  17. Centers for Disease Control and Prevention (CDC). Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep. 1999;48(26):563-5. [PubMed] 
  18. MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161-4. [Crossref]  [PubMed] 
  19. Brown KF, Kroll JS, Hudson MJ, Ramsay M, Green J, Long SJ, et al. Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review. Vaccine. 2010;28(26):4235-48. [Crossref]  [PubMed] 
  20. Rainey JJ, Watkins M, Ryman TK, Sandhu P, Bo A, Banerjee K. Reason related to non-vaccination and under-vaccination of children in low and middle income countries: findings from a systematic review of the published literature, 1999-2009. Vaccine. 2011;29(46):8215-21. [Crossref]  [PubMed] 
  21. Favin M, Steinglass R, Fields R, Banerjee K, Sawhney M. Why children are not vaccinated: a review of the grey literature. Int Health. 2012;4(4):229-38. [Crossref]  [PubMed] 
  22. Quadri-Sheriff M, Hendrix KS, Downs SM, Sturm LA, Zimet GD, Finnell SME. The role of herd immunity in parents' decision to vaccinate children: a systematic review. Pediatrics. 2012;130(3):522-30. [Crossref]  [PubMed] 
  23. Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an overview. Hum Vaccin Immunother. 2013;9(8):1763-73. [Crossref]  [PubMed]  [PMC] 
  24. Yaqub O, Castle-Clarke S, Sevdalis N, Chataway J. Attitudes to vaccination: a critical review. Soc Sci Med. 2014;112:1-11. [Crossref]  [PubMed] 
  25. McKee C, Bohannon K. Exploring the reasons behind parental refusal of vaccines. J Pediatr Pharmacol Ther. 2016;21(2):104-9. [Crossref]  [PubMed]  [PMC] 
  26. Fredrickson DD, Davis TC, Arnould CL, Kennen EM, Hurniston SG, Cross JT, et al. Childhood immunization refusal: provider and parent perceptions. Fam Med. 2004;36(6):431-9. [PubMed] 
  27. Harmsen IA, Mollema L, Ruiter RAC, Paulussen TGW, de Melker HE, Kok G. Why parents refuse childhood vaccination: a qualitative study using online focus groups. BMC Public Health. 2013;13:1183. [Crossref]  [PubMed]  [PMC] 
  28. Saada A, Lieu TA, Morain SR, Zikmund-Fisher BJ, Wittenberg E. Parents' choices and rationales for alternative vaccination schedules: a qualitative study. Clin Pediatr (Phila). 2015;54(3):236-43. [Crossref]  [PubMed] 
  29. Kennedy A, Lavail K, Nowak G, Basket M, Landry S. Confidence about vaccines in the United States: understanding parents' perceptions. Health Aff (Millwood). 2011;30(6):1151-9. [Crossref]  [PubMed] 
  30. Dubé E, Gagnon D, Nickels E, Jeram S, Schuster M. Mapping vaccine hesitancy--country-specific characteristics of a global phenomenon. Vaccine. 2014;32(49):6649-54. [Crossref]  [PubMed]  [PMC] 
  31. Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine hesitancy: causes, consequences, and a call to action. Am J Prev Med. 2015;49(6 Suppl 4):S391-8. [Crossref]  [PubMed] 
  32. Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA. 1999;282(1):47-53. [Crossref]  [PubMed] 
  33. Feikin DR, Lezotte DC, Hamman RF, Salmon DA, Chen RT, Hoffman RE. Individual and community risks of measles and pertussis associated with personal exemptions to immunizations. JAMA. 2000;284(24):3145-50. [Crossref]  [PubMed] 
  34. The Lancet Child Adolescent Health. Vaccine hesitancy: a generation at risk. Lancet Child Adolesc Health. 2019;3(5):281. [Crossref]  [PubMed] 
  35. Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K; Centers for Disease Control and Prevention (CDC). Measles outbreak--California, December 2014-February 2015. MMWR Morb Mortal Wkly Rep. 2015;64(6):153-4. [PubMed] 
  36. Omer SB, Enger KS, Moulton LH, Halsey NA, Stokley S, Salmon DA. Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. Am J Epidemiol. 2008;168(12):1389-96. [Crossref]  [PubMed] 
  37. Centers for Disease Control and Prevention (CDC). Invasive Haemophilus influenzae Type B disease in five young children--Minnesota, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(3):58-60. [PubMed] 
  38. Glanz JM, McClure DL, O'Leary ST, Narwaney KJ, Magid DJ, Daley MF, et al. Parental decline of pneumococcal vaccination and risk of pneumococcal related disease in children. Vaccine. 2011;29(5):994-9. [Crossref]  [PubMed]  [PMC] 
  39. Glanz JM, McClure DL, Magid DJ, Daley MF, France EK, Salmon DA, et al. Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. Pediatrics. 2009;123(6):1446-51. [Crossref]  [PubMed] 
  40. Atwell JE, Van Otterloo J, Zipprich J, Winter K, Harriman K, Salmon DA, et al. Nonmedical vaccine exemptions and pertussis in California, 2010. Pediatrics. 2013;132(4):624-30. [Crossref]  [PubMed] 
  41. Gangarosa EJ, Galazka AM, Wolfe CR, Phillips LM, Gangarosa RE, Miller E, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet. 1998;351(9099):356-61. [Crossref]  [PubMed] 
  42. T.C. Sağlık Bakanlığı Sağlık Bilgi Sistemleri Genel Müdürlüğü. Sağlık İstatistikleri Yıllığı 2017 Haber Bülteni. 2018.
  43. Gür E. Vaccine hesitancy-vaccine refusal. Turk Pediatri Ars. 2019;54(1):1-2. [PubMed] 
  44. Brewer NT, Chapman GB, Rothman AJ, Leask J, Kempe A. Increasing vaccination: putting psychological science into action. Psychol Sci Public Interest. 2017;18(3):149-207. [Crossref]  [PubMed] 
  45. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92. [Crossref]  [PubMed]  [PMC] 
  46. Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci. 2020;16(10):1678-85. [Crossref]  [PubMed]  [PMC] 
  47. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450-2. [Crossref]  [PubMed]  [PMC] 
  48. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-92.e6. [Crossref]  [PubMed]  [PMC] 
  49. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-23. [Crossref]  [PubMed]  [PMC] 
  50. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74. [Crossref]  [PubMed] 
  51. World Health Organization. Novel Coronavirus (2019-nCoV) situation report-22. 11 February 2020. https://apps.who.int/iris/bitstream/handle/10665/330991/nCoVsitrep11Feb2020-eng.pdf?sequence=1&isAllowed=y
  52. Tai DYH. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singapore. 2007;36(6):438-43. [PubMed] 
  53. Tai W, Zhao G, Sun S, Guo Y, Wang Y, Tao X, et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016;499:375-82. [Crossref]  [PubMed]  [PMC] 
  54. Nal B, Chan C, Kien F, Siu L, Tse J, Chu K, et al. Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. J Gen Virol. 2005;86(Pt 5):1423-34. [Crossref]  [PubMed] 
  55. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23. [Crossref]  [PubMed]  [PMC] 
  56. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9. [PubMed] 
  57. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. [Crossref]  [PubMed]  [PMC] 
  58. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. [Crossref]  [PubMed] 
  59. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142. [Crossref]  [PubMed]  [PMC] 
  60. Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, Patel R, et al. COVID-19 and older adults: what we know. J Am Geriatr Soc. 2020;68(5):926-9. [Crossref]  [PubMed]  [PMC] 
  61. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. [PubMed] 
  62. Wollina U. Challenges of COVID-19 pandemic for dermatology. Dermatol Ther. 2020;e13430. [Crossref]  [PubMed] 
  63. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-9. [PubMed] 
  64. Nicholls JM, Poon LLM, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361(9371):1773-8. [Crossref]  [PubMed] 
  65. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8-13. [Crossref]  [PubMed]  [PMC] 
  66. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J Infect. 2020;80(6):607-13. [Crossref]  [PubMed]  [PMC] 
  67. Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. 2020;20(5):277. [Crossref]  [PubMed]  [PMC] 
  68. World Health Organization. DRAFT landscape of COVID-19 candidate vaccines-20 April 2020. (Erişim tarihi: 20.4.2020) https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
  69. Norton TD, Miller EA. Corrigendum: Recent ad­vances in lentiviral vaccines for HIV-1 infec­tion. Front Immunol. 2016;7:354. [Crossref]  [PubMed] 
  70. Milone MC, O'Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529-41. [Crossref]  [PubMed]  [PMC] 
  71. Pardi N, Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. In: Kramps T, Elbers K, eds. RNA Vaccines: Methods and Protocols. 1st ed. New York: Springer Protocols Humana Press; 2016. p.109-21. [Crossref]  [PubMed] 
  72. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today. 2019;28:100766. [Crossref] 
  73. Offit PA. Deadly Choice, How the Anti-Vaccine Movement Threatens Us All. 1st ed. New York: Basic Books; 2010. p.288.
  74. Chatterjee A, O'Keefe C. Current controversies in the USA regarding vaccine safety. Expert Rev Vaccines. 2010;9(5):497-502. [Crossref]  [PubMed] 
  75. World Helath Organization. The Guide to Tailoring Immunization Programmes (TIP). 2013. (Erişim Tarihi: 20.04.2020) https://www.euro.who.int/__data/assets/pdf_file/0003/187347/The-Guide-to-Tailoring-Immunization-Programmes-TIP.pdf?ua=1

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com